

## 4DMedical lodges Supplementary Prospectus

**Melbourne, Australia, 16 April 2025:** Respiratory imaging technology company, 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) refers to its prospectus lodged with ASIC and ASX on 25 March 2025 (**Original Prospectus**) regarding the offers of New Options and Piggyback Options (**Offers**). Each New Option is exercisable at the exercise price of \$0.55 for the issue of 1 Share and 1 Piggyback Option in the Company on the earlier of 28 February 2026 and the date being 30 days from the date of the Company’s announcement of receipt of FDA clearance for its ventilation and perfusion technology, CT:VQ (if at all) (**FDA Announcement**). Each Piggyback Option will be exercisable at the exercise price of \$0.75 for the issue of 1 Share on the earlier of 29 February 2028 and the date being two years from the date of the FDA Announcement.

Given all New Options offered pursuant to the Offers are being offered for nil consideration, the Board wishes to amend the terms of the Offers such that eligible participants in the Offers will be deemed to have applied for their relevant allocation of New Options and will not need to submit a separate Application Form unless those participants wish to opt out of the Offer.

Accordingly, the Company has today lodged a supplementary prospectus dated 16 April 2025 with ASIC, which supplements the Original Prospectus.

Participants that wish to opt-out of the Offers can do so by sending requests to the Share Registry via email at [capital.markets.au@cm.mpms.mufg.com](mailto:capital.markets.au@cm.mpms.mufg.com) or by contacting the Share Registry from 8.30am to 7.30pm (Melbourne time), Monday to Friday, on 1300 554 474 (within Australia) or +61 1300 554 474 (outside Australia). Except as set out above, there have been no other changes to the terms of the Offers.

–ENDS–

Authorised by the 4DMedical Board of Directors.

### Contacts

#### Corporate and Administration

Non-Executive Director

[jsutton@4dmedical.com](mailto:jsutton@4dmedical.com)

#### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

#### Melbourne

Level 7 Melbourne Connect  
700 Swanston Street  
Carlton VIC 3053  
Tel: +61 (3) 9545 5940

#### Los Angeles

21255 Burbank Boulevard  
Suite 120  
Woodland Hills CA 91367  
Tel: +1 (818) 403-8490

4DMedical Limited  
ABN: 31 161 684 831  
Email: [info@4DMedical.com](mailto:info@4DMedical.com)  
[www.4DMedical.com](http://www.4DMedical.com)

For personal use only

# SUPPLEMENTARY PROSPECTUS

4DMedical Limited ACN 161 684 831

## 1. Important Notice

---

This Supplementary Prospectus contains particulars of changes to, and supplements, the replacement prospectus dated 25 March 2025 (**Prospectus**) issued by 4DMedical Limited ACN 161 684 831 (**Company**) in respect of the offers of New Options, with each New Option being exercisable at the exercise price of \$0.55 for the issue of 1 Share and 1 Piggyback Option in the Company on the earlier of 28 February 2026 and the date being 30 days from the date of the FDA Announcement. Each Piggyback Option will be exercisable at the exercise price of \$0.75 for the issue of 1 Share on the earlier of 29 February 2028 and the date being two years from the date of the FDA Announcement.

This Supplementary Prospectus is dated 16 April 2025 and was lodged with the Australian Securities and Investments Commission (**ASIC**) on that date. Neither ASIC nor the Australian Securities Exchange (**ASX**) take any responsibility as to the contents of this Supplementary Prospectus.

This Supplementary Prospectus must be read together with the Prospectus. To the extent of any inconsistency between this Supplementary Prospectus and the Prospectus, the provisions of this Supplementary Prospectus will prevail.

Unless otherwise indicated, terms defined and used in the Prospectus have the same meanings in this Supplementary Prospectus.

This Supplementary Prospectus and the Prospectus are important documents that should be read together, in their entirety. If you have any questions about the Offer Securities being offered under the Prospectus or any other matter, you should consult your professional advisors.

## 2. How to apply

---

Given all New Options offered pursuant to the Offers are being offered for nil consideration, the Board wishes to amend the terms of the Offers such that eligible participants in the Offers will be deemed to have applied for their relevant allocation of New Options and will not need to submit a separation Application Form unless those participants wish to opt out of the Offer.

Participants that wish to opt-out of the Offers can do so by sending requests to the Share Registry via email at [capital.markets.au@cm.mpms.mufg.com](mailto:capital.markets.au@cm.mpms.mufg.com) or by contacting the Share Registry from 8.30am to 7.30pm (Melbourne time), Monday to Friday, on 1300 554 474 (within Australia) or +61 1300 554 474 (outside Australia).

## 3. Consents

---

The Company confirms that as at the date of this Supplementary Prospectus, each of the parties that have been named as having consented to being named in the Prospectus have not withdrawn that consent.

#### **4. Target Market Determination**

---

In accordance with the design and distribution obligations under the Corporations Act, the Company has determined the target market for the offer of New Options under the Prospectus. The Company has prepared a target market determination in respect of the New Options which is available on the Company's website at <https://4dmedical.com/investor/company-information/>. The Directors have reviewed the target market determination and confirm that it remains appropriate.

#### **5. No investor action required**

---

As the content of this Supplementary Prospectus is not considered by the Company to be materially adverse to investors, no action needs to be taken by investors who seek to participate in the Offers.

#### **6. Directors' authorisations**

---

This Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of its Directors.

In accordance with section 720 of the Corporations Act, each Director has consented to the lodgement of this Supplementary Prospectus with ASIC and has not withdrawn that consent prior to lodgement.

Dated: **16 April 2025**

Signed for and on behalf of 4DMedical Limited



**Dr Andreas Fouras**  
**Managing Director and CEO**  
**4DMedical Limited**